Biotech Acquisition Company Announces Public Filing of Registration Statement on Form S-4 Related to Proposed Merger with Blade Therapeutics, Inc.

New York, NY, March 16, 2022 – Biotech Acquisition Company (NASDAQ: BIOT) (“BAC”), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, today announced that it has publicly filed, with the U.S. Securities and Exchange Commission, a registration statement on Form S-4 relating to its previously announced proposed Read more…

Biotech Acquisition Company Announces Confidential Submission of Registration Statement on Form S-4 Related to Proposed Merger with Blade Therapeutics, Inc.

New York, NY, January 3, 2022 – Biotech Acquisition Company (NASDAQ: BIOT) (“BAC”), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, today announced that it has made a confidential submission to the United States Securities and Exchange Commission (“SEC”), for receipt by the SEC on December Read more…

Biotech Acquisition Company and Blade Therapeutics Announce Definitive Merger Agreement

NEW YORK and SOUTH SAN FRANCISCO, Calif., November 3, 2021 – Biotech Acquisition Company (Nasdaq: BIOT) (“BAC”), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, and Blade Therapeutics, Inc. (“Blade”), a biopharmaceutical company based in South San Francisco, Calif., announced today that they have entered into a definitive merger agreement…

Biotech Acquisition Company Announces Separate Trading of its Class A Ordinary Shares and Warrants Commencing March 18, 2021

Biotech Acquisition Company (NASDAQ: BIOTU) (the “Company”) announced that, commencing March 18, 2021, holders of the units sold in the Company’s initial public offering may elect to separately trade the Company’s Class A ordinary shares (“Class A Ordinary Shares”) and warrants included in the units. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. The Class A Ordinary Shares and warrants that are separated will trade on the NASDAQ Capital Market under the symbols “BIOT” and “BIOTW,” respectively…

Biotech Acquisition Company Announces Pricing of $200 Million Initial Public Offering.

Biotech Acquisition Company (the “Company”), a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or other similar business combination with one or more businesses, today announced the pricing of its initial public offering of 20,000,000 units at a price of $10.00 per unit…